Matches in SemOpenAlex for { <https://semopenalex.org/work/W2066069335> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2066069335 abstract "Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DCAmrubicin, a third generation synthetic anthracycline and a potent topoisomerase (topo) II inhibitor, is approved in Japan for the treatment of lung cancer (both small-cell and non-small cell) and is being evaluated in a phase III trial in the North America and Europe for the second line treatment of SCLC. The aim of these studies was to evaluate the cross-resistance of amrubicin with other anthracyclines (doxorubicin, epirubicin) and the topo-II inhibitor etoposide, and to identify potential mechanisms of resistance to amrubicin. The doxorubicin-resistant cell lines H69-AR, MES-SA-DX5 & NCI-ADR/RES were confirmed to be resistant to doxorubicin (∼25-fold relative resistance), however, their resistance to amrubicin was low or absent (∼2-fold relative resistance). Additionally, a number of primary human ovarian and breast tumor explants that were resistant to doxorubicin and/or etoposide retained sensitivity to amrubicin. Unlike doxorubicin, amrubicin induced DNA damage, G2M cell cycle arrest and apoptosis in both doxorubicin-sensitive and -resistant lines at or below clinically relevant plasma concentrations (∼10 uM). Furthermore, in contrast to doxorubicin, fluorescence time-lapse imaging demonstrated relatively small differences in amrubicin uptake and accumulation kinetics in doxorubicin-sensitive and resistant cell lines. Using gene expression profiling studies, we showed that a greater number of genes were regulated by amrubicin than by doxorubicin in both OVCAR8 and NCI-ADR/RES lines. Amrubicin is a moderate P-glycoprotein (Pgp) substrate; however, we demonstrated that the inhibitory effect and accumulation of amrubicin is not solely modulated by Pgp in cell lines over-expressing efflux pumps including Pgp. We postulate that the high intracellular accumulation and retention of amrubicin is a result of rapid influx due to the high intrinsic permeability and lipophilic properties of amrubicin. This may explain why amrubicin overcomes pleiotropic drug resistance. In summary, we demonstrated that amrubicin has a distinct mode of action compared with other anthracyclines, is less susceptible to typical anthracycline resistance mechanisms and therefore, may be useful in the treatment of anthracycline-resistant tumors.Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr LB-59." @default.
- W2066069335 created "2016-06-24" @default.
- W2066069335 creator A5006313979 @default.
- W2066069335 creator A5007098177 @default.
- W2066069335 creator A5020381520 @default.
- W2066069335 creator A5031779697 @default.
- W2066069335 creator A5032836117 @default.
- W2066069335 creator A5086143640 @default.
- W2066069335 creator A5088579658 @default.
- W2066069335 date "2010-04-15" @default.
- W2066069335 modified "2023-09-25" @default.
- W2066069335 title "Abstract LB-59: Amrubicin, a third-generation synthetic anthracycline, is active in anthracycline-resistant tumors" @default.
- W2066069335 doi "https://doi.org/10.1158/1538-7445.am10-lb-59" @default.
- W2066069335 hasPublicationYear "2010" @default.
- W2066069335 type Work @default.
- W2066069335 sameAs 2066069335 @default.
- W2066069335 citedByCount "0" @default.
- W2066069335 crossrefType "proceedings-article" @default.
- W2066069335 hasAuthorship W2066069335A5006313979 @default.
- W2066069335 hasAuthorship W2066069335A5007098177 @default.
- W2066069335 hasAuthorship W2066069335A5020381520 @default.
- W2066069335 hasAuthorship W2066069335A5031779697 @default.
- W2066069335 hasAuthorship W2066069335A5032836117 @default.
- W2066069335 hasAuthorship W2066069335A5086143640 @default.
- W2066069335 hasAuthorship W2066069335A5088579658 @default.
- W2066069335 hasConcept C121608353 @default.
- W2066069335 hasConcept C126322002 @default.
- W2066069335 hasConcept C147897179 @default.
- W2066069335 hasConcept C185592680 @default.
- W2066069335 hasConcept C202751555 @default.
- W2066069335 hasConcept C2776694085 @default.
- W2066069335 hasConcept C2776755627 @default.
- W2066069335 hasConcept C2776802502 @default.
- W2066069335 hasConcept C2778119113 @default.
- W2066069335 hasConcept C2780835546 @default.
- W2066069335 hasConcept C2781303535 @default.
- W2066069335 hasConcept C502942594 @default.
- W2066069335 hasConcept C530470458 @default.
- W2066069335 hasConcept C55493867 @default.
- W2066069335 hasConcept C71924100 @default.
- W2066069335 hasConcept C98274493 @default.
- W2066069335 hasConceptScore W2066069335C121608353 @default.
- W2066069335 hasConceptScore W2066069335C126322002 @default.
- W2066069335 hasConceptScore W2066069335C147897179 @default.
- W2066069335 hasConceptScore W2066069335C185592680 @default.
- W2066069335 hasConceptScore W2066069335C202751555 @default.
- W2066069335 hasConceptScore W2066069335C2776694085 @default.
- W2066069335 hasConceptScore W2066069335C2776755627 @default.
- W2066069335 hasConceptScore W2066069335C2776802502 @default.
- W2066069335 hasConceptScore W2066069335C2778119113 @default.
- W2066069335 hasConceptScore W2066069335C2780835546 @default.
- W2066069335 hasConceptScore W2066069335C2781303535 @default.
- W2066069335 hasConceptScore W2066069335C502942594 @default.
- W2066069335 hasConceptScore W2066069335C530470458 @default.
- W2066069335 hasConceptScore W2066069335C55493867 @default.
- W2066069335 hasConceptScore W2066069335C71924100 @default.
- W2066069335 hasConceptScore W2066069335C98274493 @default.
- W2066069335 hasLocation W20660693351 @default.
- W2066069335 hasOpenAccess W2066069335 @default.
- W2066069335 hasPrimaryLocation W20660693351 @default.
- W2066069335 hasRelatedWork W1512853117 @default.
- W2066069335 hasRelatedWork W1969655042 @default.
- W2066069335 hasRelatedWork W1971304289 @default.
- W2066069335 hasRelatedWork W1974272691 @default.
- W2066069335 hasRelatedWork W1989443552 @default.
- W2066069335 hasRelatedWork W1993307631 @default.
- W2066069335 hasRelatedWork W1994572190 @default.
- W2066069335 hasRelatedWork W1997279577 @default.
- W2066069335 hasRelatedWork W2029389980 @default.
- W2066069335 hasRelatedWork W2031885333 @default.
- W2066069335 hasRelatedWork W2035969986 @default.
- W2066069335 hasRelatedWork W2044128437 @default.
- W2066069335 hasRelatedWork W2044798640 @default.
- W2066069335 hasRelatedWork W2065949950 @default.
- W2066069335 hasRelatedWork W2087760996 @default.
- W2066069335 hasRelatedWork W2766647878 @default.
- W2066069335 hasRelatedWork W2804876514 @default.
- W2066069335 hasRelatedWork W2984085562 @default.
- W2066069335 hasRelatedWork W3051081909 @default.
- W2066069335 hasRelatedWork W2320397822 @default.
- W2066069335 isParatext "false" @default.
- W2066069335 isRetracted "false" @default.
- W2066069335 magId "2066069335" @default.
- W2066069335 workType "article" @default.